Patent: 8,722,019
✉ Email this page to a colleague
Summary for Patent: 8,722,019
Title: | P97 fragments with transfer activity |
Abstract: | The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject. |
Inventor(s): | Jefferies; Wilfred (South Surrey, CA), Tian; Mei Mei (Coquitlam, CA), Vitalis; Timothy (Vancouver, CA) |
Assignee: | biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) |
Application Number: | 13/566,260 |
Patent Claims: | see list of patent claims |
Details for Patent 8,722,019
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Aytu Bioscience, Inc. | PROSTASCINT | capromab pendetide | Injection | 103608 | 10/28/1996 | ⤷ Try a Trial | 2031-08-05 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-08-05 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-08-05 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2031-08-05 |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2031-08-05 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-08-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |